Sofosbuvir with velpatasvir.
出版信息
Aust Prescr. 2017 Oct;40(5):200-201. doi: 10.18773/austprescr.2017.063. Epub 2017 Aug 9.
Abstract
摘要
相似文献
1
Sofosbuvir with velpatasvir.索磷布韦与维帕他韦联用。
Aust Prescr. 2017 Oct;40(5):200-201. doi: 10.18773/austprescr.2017.063. Epub 2017 Aug 9.
2
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C.索磷布韦/维帕他韦/伏西瑞韦治疗丙型肝炎的概况
Infect Drug Resist. 2019 Jul 23;12:2259-2268. doi: 10.2147/IDR.S171338. eCollection 2019.
3
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.索磷布韦/维帕他韦联合或不联合沃士韦治疗慢性丙型肝炎病毒感染患者的报告结局。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):567-574.e6. doi: 10.1016/j.cgh.2017.11.023. Epub 2017 Nov 16.
4
Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.在健康中国受试者中评估利迪帕韦/索磷布韦和索磷布韦/维帕他韦的药代动力学、安全性和耐受性。
Clin Ther. 2020 Mar;42(3):448-457. doi: 10.1016/j.clinthera.2020.01.013. Epub 2020 Feb 27.
5
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.索磷布韦/维帕他韦治疗 12 周用于终末期肾病行透析的丙型肝炎病毒感染患者。
J Hepatol. 2019 Oct;71(4):660-665. doi: 10.1016/j.jhep.2019.05.028. Epub 2019 Jun 11.
6
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.索磷布韦-维帕他韦-沃西拉帕利治疗 12 至 17 岁 HCV 感染青少年。
Hepatology. 2022 Aug;76(2):445-455. doi: 10.1002/hep.32393. Epub 2022 Mar 1.
7
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.索磷布韦和维帕他韦联合利巴韦林或不联合利巴韦林治疗丙型肝炎病毒基因型 3 感染合并肝硬化患者的疗效。
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
8
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.索磷布韦/维帕他韦/沃西西拉韦：慢性丙型肝炎治疗药物。
Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.
9
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.在肝功能损害患者中评估伏西瑞韦和索磷布韦/伏西瑞韦的药代动力学和安全性。
Clin Pharmacokinet. 2018 Nov;57(11):1449-1457. doi: 10.1007/s40262-018-0645-6.
10
HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.在稳健的感染性细胞培养模型中，丙型肝炎病毒 6a 型对韦帕他韦、哌仑他韦和索磷布韦的逃逸和耐药。
Gastroenterology. 2018 Jun;154(8):2194-2208.e12. doi: 10.1053/j.gastro.2018.02.017. Epub 2018 Feb 15.
引用本文的文献
1
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C.索磷布韦/维帕他韦/伏西瑞韦治疗丙型肝炎
Aust Prescr. 2019 Jun;42(3):108-109. doi: 10.18773/austprescr.2019.033. Epub 2019 Apr 24.
本文引用的文献
1
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.索磷布韦和维帕他韦治疗人类免疫缺陷病毒 1 型合并丙型肝炎病毒感染患者：一项开放标签、3 期研究。
Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260.
2
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.帕利瑞韦/利托那韦/奥比他韦加达拉他韦联合利巴韦林治疗慢性丙型肝炎
Aust Prescr. 2016 Aug;39(4):141-143. doi: 10.18773/austprescr.2016.045. Epub 2016 May 20.
3
Ledipasvir with sofosbuvir.来迪派韦与索磷布韦联用。
Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14.
4
Daclatasvir.达卡他韦
Aust Prescr. 2015 Dec;38(6):217-9. doi: 10.18773/austprescr.2015.077. Epub 2015 Oct 1.
5
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
6
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.索磷布韦和维帕他韦治疗 1、2、4、5、6 型 HCV 感染。
N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.
7
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.索磷布韦维帕他韦片治疗失代偿期肝硬化的丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.
Zotero 插件